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I N AN earlier study, intravenous (IV) FK 506 appeared to be less well tolerated than the oral drug for two 
reasons. 1 One was the selection of a starting IV dose that 
was too high. The other may have been the use of pulse 
infusion therapy (over 2 to 4 hours) with consequent high 
peak plasma concentrations. In patients with unsatisfac-
tory liver graft function, these peak values were sustained 
for long periods. 
In the present study, we compared the perioperative use 
of constant IV infusion of FK 506 to 4-hour pulse infusion 
in a total of 238 consecutive primary liver recipients. The 
therapeutic efficacy and adverse effects of the drug were 
compared. 
MATERIALS AND METHODS 
Case Material 
Two hundred thirty-eight patients received primary liver grafts 
under FK 506 between Feb 16 and Dec 2, 1990. A starting total 
daily IV dose of 0.15 mWIcg FK 506 was given as a constant 
infusion to 151 patients. The other 87 were given a 4-hour infusion 
of 0.075 mg/kg every 12 hours. The age, sex, and other clinical 
features of the two study groups were similar (Table I). In both 
groups, the IV FK 506 was started 2 to 4 hours after complete 
revascularization of the liver graft. Liver and kidney functions, 
FK 506 plasma levels, and doses and drug side effects were 
monitored through the 2-month study period in all survivors. 
Table 1. Characteristics of Patients with Each Infusion Method· 
Infusion 
24-11 4-h 
No. of patients 151 87 
Age (yrs, mean ± SO) 46 ± 14 49 ± 13 
Sex 
Male 91 54 
Female 60 33 
Liver disease 
Alcoholic 32 (21%) 23 (26.4%) 
Viral 26 (17%) 23 (26.4%) 
Choiestatic 24 (16%) 13 (14.9%) 
Malignant 20 (13%) 9 (10.3%) 
Miscellaneous 49 (33%) 19 (22%) 
UNOS Score 
II 4(3%) 0(0%) 
III 55 (36%) 26(30%) 
IV 92 (61%) 61 (70%) 
Serum creatinine (mg %) 1.4 ± 1.6 1.3 ± 1.5 
Positive cytotoxic cross-match 16 (11%) 11 (13%) 
'p> .05. 
FK 506 plasma levels were determined with the enzyme immu-
noassay technique of Tamura et al.2 Doses were promptly reduced 
if the preceding day's plasma levels were higher than 5 ngimL. if 
the patient had evidence of rapidly deteriorating renal function, or 
if there was evidence of neurotoxicity andlor life-threatening 
infections. Upward dose adjustments usually were prompted by a 
clinical suspicion andlor the histopathologic diagnosis of rejection 
or by low plasma levels. 
During IV therapy, the FK 506 plasma levels reflected a 12-hour 
trough when the 4-hour infusion technique was used and a 
steady-state concentration when continuous infusion was used. 
After oral therapy was begun, plasma levels usually were 12-hour 
trough values because dosing was twice a day in most of the 
patients. However, in patients with significant graft dysfunction 
andlor high plasma levels of FK 506, the drug was given once per 
day or even every other day. Here, the FK 506 levels were 24- or 
48-hour troughs. 
In 22 of the patients (13 with 4-hour infusion and 9 with 
continuous infusion). the FK 506 plasma levels were determined 
at 30- to 6O-minute intervals to obtain pharmacokinetic curves. 
Prednisone usually was started at a daily dose of 20 mg. By the 
end of the study period, 55% of all patients were completely 
weaned from steroids. Rejection episodes were treated initially in 
some patients with an increase in the doses of FK 506. Alterna-
tively, daily steroid doses were increased or steroid boluses were 
given. In 26 patients (10.9%) with an unsatisfactory response, a 3-
to 5-day course of OKT3 therapy was required. 
Statistical Analyses 
The liver recipients in each group were further stratified according 
to graft function into two subgroups: (1) those with adequate or 
excellent liver function as defined by return of the bilirubin to less 
than 2 mg % within 10 days; and (2) patients with dysfunctional 
livers from the time of operation in that the bilirubin had not fallen 
to less than 2 mg % in this interval. 
Parameters studied were function of the liver graft, kidney 
function, and evidence of neurotoxicity. Protocol biopsies were 
done in most of the patients at about day 14 postoperative. 
Biopsies at a later time were dictated by clinical andlor biochem-
ical suspicions of rejection as defined by an increase in serum 
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Fig 1. Simulation of the mean plasma concentrations of FK 506 
after 4· and 24·hour infusion of the first induction dose (0.15 
mglkg) in 13 and 9 patients, respectively. 
bilirubin, transaminases, and the canalicular enzymes to greater 
than 50% of the lowest baseline level seen early postoperatively. 
Patient, graft, and rejection·free survival were calculated using 
Kaplan-Meier survival analysis. The comparison was tested by 
using the log rank test. The rejection, hemodialysis, and neuro· 
toxicity parameters were compared between both groups by using 
the large sample Z·test. Student's t test, and Wilcoxon rank sum 
tests. 
The mean values for all of the biochemical variables and FK 506 
dose and levels were calculated for the daily values and averages 
of the first 10 postoperative days. Changes in blood urea nitrogen 
(B UN) and creatinine comparing the pretranspiant values to the 
average of the first 10 postoperative days were tested using the 
sign·rank test with Bonferroni's adjustment. The comparisons 
between two or more groups for FK S06 plasma levels. drug 
doses. BUN. and creatinine were done by Wilcoxon rank sum or 
Kruskal-Wallis chi·square approximation. Spearman correlation 
analysis was done for all quantitative parameters. All of the 
statistical analyses were performed using SAS 6.03 (SAS Institute 




The mean pharmacokinetic patterns with bolus (4 hour) vs 
continuous infusion of 0.15 mg/kg FK 506 are shown in Fig 
1. The peak concentrations following 4-hour infusion were 
nearly three times that achieved during continuous infu· 
sion. 
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Fig 2. The cumulative rejection·free rate after both methods of IV 
administration of FK 506. There was a trend to more rejection 
using continuous infusion, but the difference was not statistically 
significant (P = .09). 
Survival 
Eleven patients in each group died within the study period. 
The survival rate was 92.7% for patients with continuous 
infusion and 87.4% for those in the 4-hour infusion group. 
Sepsis was the leading cause of death in both groups. Graft 
survival was also similar in both groups, with a retrans-
plantation rate within 60 days of 10% and ll%, respec-
tively (P = .8). 
Graft Rejection 
The incidence of graft rejection was similar with both 
methods of FK 506 IV therapy with a total rate of 43% (n 
= 65) after continuous infusion and 37% (n = 32) after 
4-hour infusion. The cumulative rejection·free rate over 60 
days in those who survived that long was similar (P = .09) 
in both groups with an incidence of 58% and 68%. respec-
tively (Fig 2). The mean onset and frequency of the 
rejection episodes were also comparable in both groups 
(Table 2). One patient with the continuous infusion who 
had a strong positive direct T·lymphocyte cytotoxic cross· 
match with 100% PRA required a second graft because of 
hyperacute rejection. There were no such examples in the 
bolus group. 
Table 2. Frequency and Treatment of Rejection Episodes with Both Methods of FK 506 IV Infusion' 
Onset of First 
No. of Patients (%) Episode No. of Episodes 
Infusion Total ::;;10 d >10 d (Mean ± SO) 2 ;;,:3 
24·h 65 42 23 12 ± 12 33 14 18 
(43%) (28%) (15%) (50%) (22%) (28%) 
4·h 32 19 13 15 ± 18 14 12 6 
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Fig 3. The effect of 4·hour (every 12 hours) and continuous IV 
infusion of FK 506 within the first 15 postoperative days on FK 506 
plasma levels and renal function in liver allograft recipients. 
FK 506 Doses and Drug Plasma Levels 
The means during the first IS days of the daily FK 506 
doses and plasma levels were plotted in Fig 3, showing the 
trough levels after bolus administration vs the steady-state 
levels in patients on continuous infusion. The mean doses 
as well as the FK 506 plasma levels were significantly 
higher (P < .00(1) with 4·hour infusion compared to 
continuous therapy. The dose differences were due to 
more aggressive and rapid downward dose adjustments in 
the constant infusion group. 
Kidney Function 
Hemodialysis. Renal failure severe enough to necessi-
tate hemodialysis developed in the postoperative period in 
a total of 3S patients (14.7%). Nineteen of these patients 
received continuous infusion (13%) and 16 were treated 
with 4-hour infusion (18%). The onset of posttransplant 
renal failure was similar in both groups with mean values 
of 13 ± 10 days (24-hour) and 12 ± 10 days (4-hour). 
Prolonged posttransplant liver graft dysfunction was con-
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Fig 4. The development of posttransplant renal failure and the 
mean of the average of the first 10-day serum bilirubin, FK 506 
dose, and drug plasma level. 
cases in the respective groups. Recovery of the kidney 
function occurred in all but one of the continuous infusion 
and all but three of the 4-hour infusion morbid cases who 
died within the study period. 
The means of the average of the first 10-day values of 
FK 506 doses, plasma levels, and serum bilirubin for 
patients who required hemodialysis vs those who main-
tained their renal function are depicted in Fig 4. Patients 
with good liver function were given more FK S06, but had 
lower plasma FK 506 levels and less need for dialysis (P < 
.00(1). 
BUN and Serum Creatinine. Blood urea nitrogen and 
serum creatinine were significantly increased postopera-
tively with both methods of FK 506 infusion (Fig 3). The 
maximal rises occurred within the first 10 days after 
transplantation. The average values during that period 
were significantly (P = .04) higher with the 4-hour infusion 
compared to the continuous therapy. In all patients, a 
significant correlation was observed between the simulta-
neously measured FK S06 plasma level and serum creati-
nine (r = .49, P = .001). 
Neurotoxicity 
Acute neurologic dysfunctions in the form of confusion, 
paranoid illusion, seizure, and akinetic mutism developed 
in a total of 14 patients: 9 after 4-hour infusion (10.3%) and 
S after continuous (3.3%) therapy. The difference was 
statistically significant (P = .04). The time of onset was 
similar in both groups with a mean of 12 ± 11 and 15 ± 12 
days, respectively. At the time of neurotoxic symptoms, 
the serum bilirubin level was high with a mean value of 4 ± 
4 mg % (4-hour) and 3 ± 3 mg % {24-hour). The FK 506 
12-hour trough plasma levels were also high in both 
groups, with a mean value of 2.S ± 2 nglmL with the 
4-hour infusion and 3.4 ± 4 nglmL with the 24-hour 
infusion. Prolonged IV therapy was in effect for most 
patients who developed neurotoxicity. 
Effect of Graft Function 
With each infusion method, patients with significant graft 
dysfunction (class II) had higher FK 506 plasma levels and 
2no 
lower IV doses compared to those with good functioning 
liver grafts (class I) with P values of .0001 and .009, 
respectively. A significant positive correlation was also 
noticed between serum bilirubin and FK 506 plasma level 
at all points during the study period (r = .5, P = .(01). 
BUN and creatinine were significantly(P < .04) increased 
in class II compared to class I patients. 
DISCUSSION 
These studies suggest that continuous vs bolus dosing of 
FK 506 can reduce the incidence of renal failure, which 
requires dialysis. and the incidence of neurologic compli-
cations. Both renal failure and neurotoxicity appear to be 
correlated positively with the plasma concentration of FK 
506, and in turn the plasma concentration was a function of 
the height of the serum bilirubin. This was not surprising 
because the profound effect of hepatic dysfunction on the 
elimination of FK 506 was emphasized in earlier publica-
tions.1.3-6 
The seeming advantage of continuous vs bolus infusion 
could be illusory and more the consequence of the total 
dose given than the rate of administration. The patients 
treated with continuous infusion had more aggressive dose 
adjustment at the first sign of drug toxicity and more 
quickly available results from the plasma monitoring. 
Co'ilsequently, their doses were cut at an earlier time with 
th{ result that the mean daily dosages were significantly 
less than in the bolus group. Nevertheless, that may have 
been an advantage to avoiding the peak FK 506 plasma 
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concentration that occurred soon after completion of the 
bolus. It was of interest that therapeutic levels from a 
single bolus were maintained throughout the full 24-hour 
period. 
Our recommendation, based on this experience, is that 
FK 506 should be given by constant infusion with very 
close attention to the steady-state plasma levels of the 
drugs. During the critical perioperative period, it is prob-
able that the plasma FK 506 levels should be kept in the 
2-3 ng/mL range, but the optimal therapeutic zone has not 
yet been determined. The technique presented at this 
meeting by McMichael et al7 for algorithmic dose adjust-
ment should help in more accurately defining the ideal 
therapeutic range. 
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